Biotech
Monday, July 22nd, 2024 2:49 pm EDT
Key Points
- Increased Private Placement: Rakovina Therapeutics Inc. is upsizing its previously announced private placement from $2.0 million to $2.3 million, pending approval from the TSX Venture Exchange. The terms of the private placement will remain the same, with the anticipated closing date around July 22, 2024.
- Focus on Cancer Treatments: Rakovina Therapeutics is dedicated to developing new cancer therapies through novel DNA-damage response technologies. The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials and seek marketing approval from regulatory agencies like Health Canada and the U.S. Food and Drug Administration.
- Regulatory and Market Goals: Rakovina Therapeutics is working towards obtaining approval for its new cancer therapeutics from major international regulatory agencies, with the goal of bringing innovative treatments to market.
Rakovina Therapeutics Inc., further to the news releases dated May 23, 2024, and June 20, 2024, to accommodate additional indications of interest, will upsize the previously announced private placement of $2.0-million to $2.3-million, subject to TSX Venture Exchange ) approval. The terms of the private placement otherwise remain unchanged. The company now anticipates closing the private placement on or about July 22, 2024.
About Rakovina Therapeutics Inc.
Rakovina is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials, and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration, and similar international regulatory agencies.
We seek Safe Harbor.
